Loading institutional data...
Loading institutional data...
Held by 408 of 2,417 reporting institutions (98th percentile) — extremely crowded.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Ranked against 23 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.22T | 59.9× | — | 18.8× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 1,730 |
| JNJ | $662.5B | 24.9× | 21.0× | 7.0× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | 0.9× | 1,839 |
| ABBV | $513.9B | 123.2× | 36.4× | 8.4× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 3.9× | 1,635 |
| MRK | $361.0B | 20.1× | — | 5.5× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 1,469 |
| ABT | $180.9B | 28.1× | 19.5× | 4.1× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 0.5× | 1,081 |
| PFE | $170.7B | 22.0× | — | 2.7× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 1,034 |
| VRTX | $136.9B | 35.3× | 30.1× | 11.4× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | -1.2× | 568 |
| BMY | $125.4B | 17.7× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 904 |
| REGN | $84.3B | 19.7× | 20.2× | 5.9× | 1.0% | — | 31.4% | 14.4% | 13.6% | -0.3× | 408 |
| TEVA | $48.4B | 34.3× | 18.1× | 2.8× | 4.3% | 51.8% | 8.2% | 17.8% | 14.5% | -0.7× | 7 |
| ONC | $42.3B | — | 65.7× | 7.9× | 40.2% | 87.5% | 5.4% | 6.6% | 5.4% | -6.1× | 61 |
| ZTS | $32.6B | 13.1× | 10.3× | 3.4× | 2.3% | 71.8% | 28.2% | 78.3% | 21.5% | 1.7× | 388 |
| RPRX | $29.4B | 37.0× | 24.1× | 12.3× | 5.1% | — | 32.4% | 7.9% | 4.1% | 5.3× | 161 |
| UTHR | $25.5B | 21.3× | 15.1× | 8.0× | 10.6% | 87.9% | 41.9% | 18.8% | 18.8% | -1.0× | 202 |
| INSM | $24.4B | — | — | 40.2× | 66.7% | 79.7% | -211% | -173% | -99.8% | — | 154 |
| ALNY | $23.3B | 74.7× | 38.9× | 6.3× | 65.2% | 81.8% | 8.4% | 39.8% | 39.8% | -3.0× | 163 |
| ELAN | $11.6B | — | — | 2.5× | 6.2% | 55.0% | -4.9% | -3.5% | -2.2% | — | 122 |
| BMRN | $11.1B | 31.9× | 21.3× | 3.5× | 12.9% | 77.7% | 10.8% | 5.7% | 5.2% | -1.5× | 119 |
| CORT | $9.3B | 104.8× | 199.6× | 12.2× | 12.8% | 98.3% | 13.1% | 15.4% | 15.4% | -2.6× | 107 |
| TGTX | $8.9B | 21.0× | 73.4× | 14.4× | 87.3% | 83.7% | 72.6% | 69.0% | 50.0% | 1.4× | 99 |
| KNSA | $7.7B | 130.1× | 96.9× | 11.3× | 60.1% | 88.5% | 8.7% | 10.4% | 10.4% | -2.1× | 1 |
| ALKS | $7.6B | 31.7× | 25.7× | 5.2× | -5.2% | 86.7% | 16.4% | 13.3% | 13.3% | -1.4× | 74 |
| AMRX | $7.4B | 97.0× | 21.6× | 2.5× | 8.0% | 36.9% | 2.4% | -102% | 2.9% | 5.1× | 73 |
| IONS | $7.4B | — | — | 7.8× | 33.8% | 98.3% | -40.4% | -78.0% | -17.0% | — | 81 |
Peers = companies sharing REGN's sector (Pharmaceutical Preparations) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
The same 3 years as the 3-yr average, with the stock compensation of those years charged as a cost. Shares issued to employees are real dilution, so this asks what the business generates for existing holders.
To be worth $927.89 today, the market must believe free cash flow compounds 10.4%/yr for a decade (off $2.92B on the SBC-adjusted basis).
On the basis ($3.87B) the requirement is 6.8%/yr. The difference is what charging stock compensation costs.
The market's 10.4% is more conservative than its 9-yr track record.
Default is 8.3% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.10B shares (market data) · net debt -$1.13B
mean 47.6% · volatility σ 104% · implied rate exceeded in 5/9 yrs
Central path = implied 10.4%/yr growth; shaded band = ±1σ (104%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 9% of free cash flow, leaving room to grow it and fund buybacks. Last year: $370.3M dividends + $3.44B buybacks = $3.81B returned on $4.08B FCF.
1 consecutive years of dividend increases.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 14%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B 100.0% | $14.20B 100.0% | $13.12B 100.0% | $12.17B 100.0% | $16.07B 100.0% | $8.50B 100.0% | $6.56B 100.0% | $5.15B 100.0% | $5.87B 100.0% | $4.86B 100.0% |
| Cost of Revenue | — | — | — | — | — | — | $402.8M 6.1% | $237.5M 4.6% | $202.5M 3.4% | $194.6M 4.0% |
| Cost of Products | — | — | — | — | — | — | — | — | $202.5M 3.4% | $194.6M 4.0% |
| Research & Development | $5.85B 40.8% | $5.13B 36.1% | $4.44B 33.8% | $3.59B 29.5% | $2.86B 17.8% | $2.65B 31.2% | $2.45B 37.4% | $1.47B 28.5% | $2.08B 35.3% | $2.05B 42.2% |
| Selling, General & Admin | $2.70B 18.8% | $2.95B 20.8% | $2.63B 20.1% | $2.12B 17.4% | $1.82B 11.4% | $1.35B 15.8% | $1.34B 20.5% | $1.13B 21.9% | $1.32B 22.5% | $1.18B 24.2% |
| Total Operating Expenses | $10.77B 75.1% | $10.21B 71.9% | $9.07B 69.1% | $7.43B 61.1% | $7.12B 44.3% | $4.92B 57.9% | $4.35B 66.3% | $2.61B 50.7% | $3.79B 64.6% | $3.53B 72.6% |
| Operating Income | $3.58B 24.9% | $3.99B 28.1% | $4.05B 30.9% | $4.74B 38.9% | $8.95B 55.7% | $3.58B 42.1% | $2.21B 33.7% | $2.53B 49.3% | $2.08B 35.4% | $1.33B 27.4% |
| Interest Expense | $43.8M 0.3% | $55.2M 0.4% | $73.0M 0.6% | $59.4M 0.5% | $57.3M 0.4% | $56.9M 0.7% | $30.2M 0.5% | $28.2M 0.5% | $25.1M 0.4% | $7.2M 0.1% |
| Other Income (Expense), net | $1.65B 11.5% | $789.2M 5.6% | $152.2M 1.2% | $119.9M 1.0% | $379.0M 2.4% | $233.8M 2.8% | $219.3M 3.3% | $19.1M 0.4% | -$1.1M -0.0% | -$900K -0.0% |
| Pretax Income | $5.23B 36.5% | $4.78B 33.7% | $4.20B 32.0% | $4.86B 39.9% | $9.33B 58.0% | $3.81B 44.8% | $2.43B 37.0% | $2.55B 49.6% | $2.08B 35.4% | $1.33B 27.4% |
| Income Tax Expense | $725.8M 5.1% | $367.3M 2.6% | $245.7M 1.9% | $520.4M 4.3% | $1.25B 7.8% | $297.2M 3.5% | $313.3M 4.8% | $109.1M 2.1% | $880.0M 15.0% | $434.3M 8.9% |
| Net Income | $4.50B 31.4% | $4.41B 31.1% | $3.95B 30.1% | $4.34B 35.6% | $8.08B 50.2% | $3.51B 41.3% | $2.12B 32.3% | $2.44B 47.5% | $1.20B 20.4% | $895.5M 18.4% |
| Per Share | ||||||||||
| EPS (Basic) | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 | $11.27 | $8.55 |
| EPS (Diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 |
| Weighted Avg Shares (Basic) | 104.6M | 107.9M | 106.7M | 107.1M | 105.7M | 107.6M | 109.2M | 107.9M | 106.3M | 104.7M |
| Weighted Avg Shares (Diluted) | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M | 114.6M | 114.8M | 115.9M | 116.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~2.2% on $1.99B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 14-yr range · 46th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 14% against ROIC 14% — 1% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 4.6 | 6.1 | — | — | — | — | — | — |
| R&D | 28.5 | 37.4 | 31.2 | 17.8 | 29.5 | 33.8 | 36.1 | 40.8 |
| SG&A | 21.9 | 20.5 | 15.8 | 11.4 | 17.4 | 20.1 | 20.8 | 18.8 |
| Operating Income | 49.3 | 33.7 | 42.1 | 55.7 | 38.9 | 30.9 | 28.1 | 24.9 |
| Income Tax | 2.1 | 4.8 | 3.5 | 7.8 | 4.3 | 1.9 | 2.6 | 5.1 |
| Net Income | 47.5 | 32.3 | 41.3 | 50.2 | 35.6 | 30.1 | 31.1 | 31.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on REGN: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
The spread has compressed 4 years running.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2019 | 19.5% | 8.3% (today's — no rate published for this year) | 11.1pts |
| FY2020 | 27.8% | 8.3% (today's — no rate published for this year) | 19.4pts |
| FY2021 | 43.0% | 4.6% | 38.4pts |
| FY2022 | 19.1% | 7.8% | 11.3pts |
| FY2023 | 14.0% | 7.6% | 6.4pts |
| FY2024 | 12.1% | 8.6% | 3.4pts |
| FY2025 | 10.3% | 8.1% | 2.2pts |
| Now | 13.6% | 8.3% | 5.2pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 96.0% | 27.4% | 18.4% |
| FY2017 | 96.6% | 35.4% | 20.4% |
| FY2018 | 95.4% | 49.3% | 47.5% |
| FY2019 | 93.9% | 33.7% | 32.3% |
| FY2020 | not reported | 42.1% | 41.3% |
| FY2021 | not reported | 55.7% | 50.2% |
| FY2022 | not reported | 38.9% | 35.6% |
| FY2023 | not reported | 30.9% | 30.1% |
| FY2024 | not reported | 28.1% | 31.1% |
| FY2025 | not reported | 24.9% | 31.4% |
Return on equity (14%) and return on invested capital (14%) are within a couple of points in FY2025, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
The spread is 1.98pts and would invert under a ±2% move in WACC, so the verdict rests on the cost-of-capital assumption rather than on the business.
Converts 0.91x of reported profit into free cash flow over 5 years, with accruals negative.
Reported free cash flow is $4.08B; after share-based compensation it is $3.09B. The difference is a real cost that the cash flow statement adds back.
Covers interest 57.2x even after a 30% EBITDA decline.
| EBITDA decline | Interest coverage |
|---|---|
| 0% | 81.69x |
| 5% | 77.60x |
| 10% | 73.52x |
| 15% | 69.43x |
| 20% | 65.35x |
| 25% | 61.27x |
| 30% | 57.18x |
| 35% | 53.10x |
| 40% | 49.01x |
| 45% | 44.93x |
| 50% | 40.84x |
| 55% | 36.76x |
| 60% | 32.67x |
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
The maturity schedule is not part of this verdict — its filing anchor is often older than the balance sheet it sits beside, so a wall inside 24 months may not be visible here.
At $927.89, free cash flow must compound 10.55%/yr for 10 years. It has done 12.33%/yr over 6 years after stock compensation.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | 2.3% | 10.5% |
| FY2021 | 277.2% | 10.5% |
| FY2022 | −37.6% | 10.5% |
| FY2023 | −19.2% | 10.5% |
| FY2024 | −10.3% | 10.5% |
| FY2025 | 15.1% | 10.5% |
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM (share count from the last fiscal year — the TTM window reports none).
This is solved on free cash flow AFTER stock compensation ($2.92B against $3.87B before it). On the unadjusted figure the requirement would be 6.89%/yr. Which is right depends on whether you think the share issuance is a recurring cost of running the business.
| Step | Amount | Running total |
|---|---|---|
| Net income | $4.50B | $4.50B |
| Share-based comp | $994M | $5.50B |
| Other non-cash & working capital | −$520M | $4.98B |
| Operating cash flow | $4.98B | $4.98B |
| Capex | −$898M | $4.08B |
| Free cash flow | $4.08B | $4.08B |
| FCF after SBC | $3.09B | $3.09B |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | 29.6% | 95.9% | 66.4 points |
| FY2021 | 89.1% | 46.7% | -42.4 points |
| FY2022 | -24.3% | -11.7% | 12.5 points |
| FY2023 | 7.8% | 6.3% | -1.4 points |
| FY2024 | 8.3% | 9.6% | 1.3 points |
| FY2025 | 1.0% | -7.6% | -8.6 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 116.9 days | 1282.7 days | 378.9 days | 1020.7 days |
| FY2020 | 176.8 days | not reported | not reported | not reported |
| FY2021 | 137.1 days | not reported | not reported | not reported |
| FY2022 | 159.8 days | not reported | not reported | not reported |
| FY2023 | 157.7 days | not reported | not reported | not reported |
| FY2024 | 159.6 days | not reported | not reported | not reported |
| FY2025 | 146.1 days | not reported | not reported | not reported |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -2.1 percent |
| FY2020 | 5.2 percent |
| FY2021 | 3.9 percent |
| FY2022 | -2.3 percent |
| FY2023 | -1.9 percent |
| FY2024 | -0.0 percent |
| FY2025 | -1.2 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 6 | $753.76 | $5k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 35 | $755.91 | $26k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 16 | $757.68 | $12k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
| 24 |
| $758.16 |
| $18k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 14 | $759.96 | $11k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 74 | $760.65 | $56k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 27 | $761.36 | $21k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 55 | $762.57 | $42k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 25 | $763.76 | $19k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 219 | $764.40 | $167k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 271 | $765.39 | $207k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 279 | $766.47 | $214k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 192 | $767.39 | $147k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 105 | $768.33 | $81k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 127 | $769.30 | $98k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 12 | $770.20 | $9k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 283 | $771.56 | $218k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 211 | $772.56 | $163k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 224 | $773.40 | $173k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 121 | $774.48 | $94k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 376 | $775.46 | $292k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 66 | $776.31 | $51k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 38 | $777.76 | $30k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 454 | $778.64 | $354k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 380 | $779.59 | $296k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 463 | $780.63 | $361k |
| 2026-10-14 | 30 co-filers Co-Chief Scientific Officer | 10b5-1 plan sale | 50 | $781.47 | $39k |
| 2026-10-13 | 30 co-filers Co-Chief Scientific Officer | Option exercise | 17,000 | $381.92 | $6.5m |
| 2026-10-13 | 30 co-filers Co-Chief Scientific Officer | Tax withholding | 12,853 | $754.58 | $9.7m |
| 2026-10-13 | 30 co-filers Co-Chief Scientific Officer | Option exercise | 17,000 | $0.00 | — |
| 2026-09-03 | 2 co-filers EVP Commercial | 10b5-1 plan sale | 1,131 | $857.39 | $970k |
| 2026-09-02 | 3 co-filers Group filing | Option exercise | 400 | $719.37 | $288k |
| 2026-09-02 | 2 co-filers EVP Commercial | 10b5-1 plan sale | 1,215 | $850.00 | $1.0m |
| 2026-09-02 | 3 co-filers Group filing | 10b5-1 plan sale | 400 | $850.00 | $340k |
| 2026-09-02 | 3 co-filers Group filing | Option exercise | 400 | $0.00 | — |
| 2026-08-19 | 3 co-filers EVP General Counsel and Secret | Option exercise | 12,282 | $381.92 | $4.7m |
| 2026-08-19 | 3 co-filers EVP General Counsel and Secret | Tax withholding | 9,019 | $830.15 | $7.5m |
| 2026-08-19 | 3 co-filers EVP General Counsel and Secret | Option exercise | 12,282 | $0.00 | — |
| 2026-08-18 | 3 co-filers EVP Finance CFO | Option exercise | 6,283 | $381.92 | $2.4m |
| 2026-08-18 | 3 co-filers EVP Finance CFO | Tax withholding | 4,599 | $813.47 | $3.7m |